-
Company Insights
Innovation and Patenting activity of Merus NV Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Merus NV Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Metastatic Breast Cancer Drug Details: Zenocutuzumab (MCLA-128) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Non-Small Cell Lung Cancer Drug Details: MCLA-129 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Paranasal Sinus And Nasal Cavity Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Paranasal Sinus And Nasal Cavity Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Paranasal Sinus And Nasal Cavity Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Solid Tumor Drug Details: Zenocutuzumab (MCLA-128) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Non-Small Cell Lung Cancer Drug Details: Zenocutuzumab (MCLA-128)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Pancreatic Ductal Adenocarcinoma Drug Details: Zenocutuzumab (MCLA-128) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rucaparib Camsylate in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucaparib Camsylate in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucaparib Camsylate in Metastatic Pancreatic Cancer Drug Details: Rucaparib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCA-32459 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCA-32459 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCA-32459 in Head And Neck Squamous Cell...